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Abstract
Introduction: Autoantibodies against mutated and citrullinated vimentin (MCV) represent a novel diagnostic marker 
for rheumatoid arthritis (RA). Recently, an increased sensitivity for anti-MCV compared to autoantibodies against cyclic 
citrullinated peptides (anti-CCP2) was shown in cohorts of patients with early RA and established disease.
The aim of this study was to develop and evaluate a point of care test (POCT) for detection of anti-MCV antibodies
immediately at the first visit or at the bed side.
Methods: A lateral-flow immunoassay was developed for simultaneous detection of anti-MCV antibodies and 
rheumatoid factor (RF-IgG) and evaluated in a prospective setting. Analyses were performed from whole blood 
samples of patients with seropositive RA (n = 108), seronegative RA as well as other rheumatic disorders (n = 122), and 
healthy blood donors (n = 200) and compared to detection via ELISA.
Results: Using the POCT, anti-MCV antibodies were detected in 54.6% and RF-IgG in 56.5% of patients with RA. 
Specificity was 99.1% for anti-MCV antibodies and 91.2% for RF-IgG. Compared to ELISA's results, POCT sensitivity was 
69.3% for anti-MCV and 55.6% for RF-IgG, specificity was 99.7% and 97.2%, respectively.
Conclusions: This POCT for detection of anti-MCV antibodies and RF-IgG provides high specificity for the diagnosis of 
RA and is useful in clinical practice due to its simplicity and its reliable performance. This test can greatly improve a 
timely management of RA and may help in screening patients with suspected RA in non-specialized settings 
prompting early referrals.
Introduction
Rheumatoid arthritis (RA) is the most common chronic
autoimmune arthritis worldwide leading to disability and
substantial economic costs [1,2]. For improving the over-
all outcome and to prevent irreversible joint damages,
early diagnosis and therapy are crucial. However, the ini-
tial clinical signs of RA are often non-characteristic,
rather resembling undifferentiated arthritis. Detection of
autoantibodies against citrullinated protein/peptide anti-
gens (ACPA) substantially improved our diagnostic rep-
ertoire providing moderate sensitivity and high
specificity for early-RA. Recently, we identified a novel
antigenic isoform of vimentin in patients with rheuma-
toid arthritis, which was modified by citrullination and
mutation (MCV) [3]. Subsequently, several investigators
in different cohorts of patients with rheumatoid arthritis
reported on diagnostic performance for anti-MCV anti-
body testing ranging from 69 to 82% for sensitivity and
reaching 81 to 98% for specificity [3-12].
To further facilitate ACPA testing, a point of care test
(POCT) was developed for a rapid and combined detec-
tion of rheumatoid factor (RF) and anti-MCV-antibodies.
This rapid test can be performed from one single drop of
whole blood and does not require any additional equip-
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ment. To evaluate the diagnostic performance of this
novel POCT for RF-IgG and anti-MCV-antibodies and
compare it with established procedures, a prospective
study was performed in patients with RA.
Materials and methods
Patients
In this study, 108 patients with (thus far) seropositive RA
fulfilling the revised ACR criteria, 122 patients with sero-
negative RA and other rheumatic disorders, and 200
healthy blood donors were analyzed for anti-MCV and
RF-IgG seropositivity using the POCT as well as com-
mercially available ELISAs (See Table 1 for patients' char-
acteristics).
Main diagnoses in the control group were ankylosing
spondylitis (n = 21), psoriatic arthritis (n = 21), seronega-
tive course of rheumatoid arthritis (n = 20) and Sjögrens'
syndrome (n = 9), polymyalgia rheumatica (n = 8), sys-
temic vasculitis (n = 7), systemic lupus erythematosus (n
= 7), Lyme borreliosis (n = 6) and osteoarthritis (n = 6)
(all patient diagnoses are listed in Additional file 1).
All patients were recruited from the in- and outpatient
clinics of the Department of Rheumatology at the Chari-
té-Universitätsmedizin Berlin and at the Rheumaklinik
Berlin-Buch. The study was approved by the local Ethics
Committee, and blood samples were obtained after writ-
ten informed consent.
Lateral-flow immunochromatographic device
Lateral-flow immunochromatographic assay (LFIA) was
manufactured as double antigen direct sandwich assa y .
Devices (DCN, Carlsbad, CA, USA) for testing of up to 10
μl of biological samples were produced by mounting a
nitrocellulose membrane (Thickness, 205 ± 1 μm) (Milli-
pore, Billerica, MA, USA) to a plastic support. Purified
recombinant MCV and purified Fc-part of human immu-
noglobulin (approximately 1 mg/ml each) were striped in
two test line (MCV and RF) positions, while protein L
(0.5 mg/ml) (Sigma, St. Louis, MO, USA) was striped in
the control line position C. Gold particles (40 nm, British
BioCell International), were individually conjugated to
goat anti-human IgG and IgM (Dianova, Hamburg, Ger-
many) and mixed. Anti-human immunoglobulin colloidal
gold conjugate was dispensed onto a conjugate pad
(Arista Biologicals, Allentown, PA, USA). The conjugate
pad was then affixed to the test strip by overlapping the
nitrocellulose membrane at its proximal end. The assem-
bly was completed by addition of a sample pad onto the
conjugate pad. Assay buffer consists of 20 mM Tris, 0.01%
sodium azide, 250 mM NaCl, 0.05% Tween 20. Test per-
formance was stable for at least 24 months after manufac-
ture by storage at room temperature.
Direct antibody sandwich format
A blood drop (approximately 20 μl) was placed in the
sample port at A on the device. After adding six drops of
assay buffer into the buffer port B, patients' antibodies
migrated down to the nitrocellulose membrane by capil-
lary action. At the test line T anti-MCV or RF bound to
their respective immobilized antigens. By adding an assay
buffer, the anti-human IgG gold conjugate was resus-
pended, and after migration on the nitrocellulose mem-
brane indicated the autoantibody-antigen complexes
formed as a red line. Non-MCV and RF specific antibod-
ies migrated to the control line C and were visualized by
gold-conjugated anti-human IgG.
During development of the assay, the amount of gold-
conjugated anti-human IgG, the number of conjugated
colloidal gold particles, and the amount of anti-human
IgG were empirically titrated to yield a distinct line at the
test positions using a serum sample with a reactivity of
approximately 100 U/ml in both standardized anti-MCV
and RF-ELISA (Orgentec, Mainz, Germany).
The ratio of applied antigens and serum anti-MCV
antibodies and/or RF was such that monodentate binding
of autoantibodies to the epitopes was favoured on the
basis of steric and other conditions. Subsequently, biden-
tate antibody binding was favoured at the two test lines,
an anti-MCV and a RF-IgG binding sites, due to the
extremely high concentration of antigens (approximately
2 mg/ml). Once optimized, this process became indepen-
dent of the concentration of serum anti-MCV and RF.
The colour formation for all reactions was completed
after 10 to 15 minutes. The device provides an integrated
Table 1: Patients' characteristics
RA patients Control group Healthy blood donors
total 108 122 200
female/male (n) 87/21 84/38 139/61
age mean (SD) 57.9 (13.8) 57.1 (14) 47.4 (19.1)
SD, standard deviationRenger et al. Arthritis Research & Therapy 2010, 12:R120
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control system indicating correct test performance or
invalid test results. See Figure 1 for possible result con-
stellation.
Serum samples and whole blood samples were run in
the LFIA device, and the values were compared to ELISA-
derived anti-MCV and RF concentrations, respectively.
Results were dichotomized on the basis of being above or
below the limit of quantification of the ELISA (cut-off
anti-MCV 40 U/ml, cut-off RF-IgG 30 U/ml).
ELISA
Anti-MCV antibodies (cut-off 20 U/ml) and RF-IgG (cut-
off 20 U/ml) were determined by an ELISA (Orgentec).
Statistics
Sensitivity, specificity and predictive values were calcu-
lated according to the appropriate formula. Sensitivity
was exclusively calculated within the RA group. Specific-
ity was calculated against rheumatic diseases and a
healthy control group. In this study, prevalence was con-
sidered as the ratio of seropositive RA patients against all
patients with rheumatic diseases (n = 230).
Results
Whole blood samples of 108 patients with seropositive
RA underwent LFIA testing and showed 59 positive anti-
MCV results and 61 positive RF-IgG results, reflecting a
diagnostic sensitivity of 54.6% for anti-MCV and 56.5%
for RF-IgG (Table 2). The positive POCT results were
confirmed by ELISA in 98.3% and 95.1% of the cases,
respectively. Testing 122 patients with other rheumatic
disorders led to no positive anti-MCV results in POCT
and 10 positive RF-IgG samples (Table 3). In contrast,
Figure 1 Results.
invalid
negative
RF positive 
MCV positive 
RF and MCV 
positive 
Table 2: Results of Anti-MCV and RF IgG testing using POCT in 
comparison to ELISA
POCT Anti-MCV RF IgG
positive (n) 62 87
negative (n) 368 343
sensitivity relating to diagnosis (%) 54.6 56.5
specifity relating to diagnosis (%) 99.1 91.2
PPV relating to diagnosis (%) 100
NPV relating to diagnosis (%) 71.3
sensitivity relating to ELISA (%) 69.3 55.6
specifity relating to ELISA (%) 99.7 97.2
PPV, positive predictive value; NPV, negative predictive valueRenger et al. Arthritis Research & Therapy 2010, 12:R120
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ELISA for anti-MCV antibodies was positive with 4 and
for RF with 35 patients. Therefore, specificity for MCV
was 99.1% and for RF 91.2% using the POCT. Analysis of
200 healthy blood donors revealed 3 anti-MCV positive
and 16 RF-IgG positive results, which were confirmed by
ELISA in 100% and 93.7% of the cases, respectively
(Tables 2 and 3).
The positive predictive value of anti-MCV positivity
regarding the diagnosis RA was 100% and the negative
predictive value was 71.3% using the POCT. Having
defined the ELISA results as the gold standard these
results led to an overall sensitivity of 69.3% for detection
of anti MCV antibodies and of 55.6% for RF-IgG as well
as to a specificity of 99.7% for MCV and of 97.2% for RF-
IgG. Overall, correlation between both methods was 93%
regarding detection of anti-MCV antibodies and 83%
regarding detection of RF-IgG in all 430 samples. There
was no invalid test result among all 430 samples.
Discussion
At an early undifferentiated stage of disease diagnosing
RA can be difficult and challenging as clinical manifesta-
tion may appear oligosymptomatic, intermittent, or
asymmetric, not yet fulfilling the current classification
criteria of the disease. However, major joint damage and
loss of function occur during the first months and years
of the disease. Thus, early diagnosis and consecutive
treatment with disease modifying anti-rheumatic drugs
(DMARDs) are essential in order to manage rheumatoid
arthritis successfully. Former studies investigating lag
time from symptom onset to administration of antirheu-
matic drugs showed that the greatest time loss occurs
either during the diagnosis of RA or the time until refer-
ral to a rheumatologist. Once diagnosis was made or
patients were seen by a rheumatologist, antirheumatic
therapy was administered within a few weeks only
[13,14]. Therefore, a POCT providing immediate results
for a highly specific marker for RA such as anti-MCV
antibodies applied at the primary care doctor's practice
with a patient with unclear joint symptoms and suspected
RA can accelerate referral to the specialist leading to
more detailed laboratory tests, earlier diagnosis and ther-
apy. Moreover, in rural settings or in developing countries
more elaborate test systems such as ELISA may not be
available or their results may take too long to be taken
into account.
In this study, a mid-range sensitivity and excellent diag-
nostic specificity were documented for the simultaneous
detection of anti-MCV antibodies and RF-IgG using
POCT. As a major technical difference to established
immunoassays, this POCT is based on the ability to
detect anti-MCV antibodies and RF from one single drop
of whole blood. It does not require washing steps or spe-
cial equipment. Results come within 15 minutes. The test
result can be evaluated visually, typically by recognition
of up to two test lines (RF and MCV) and a control line
for correct test performance. Therefore, this test might be
extremely useful in clinical practice due to simple and
reliable performance. Moreover, by providing a high
specificity for RA, this test allows an excellent point of
care testing. Although false positive results are rare, posi-
tive reactivity in POCT should be confirmed by using a
standard immunoassay such as an ELISA.
The POCT we investigated in this study is the first
POCT testing for anti-MCV antibodies and RF-IgG. RF-
Ig G,  a lt hough of  l im it ed cl inica l val ue ,  was  c hose n f o r
reasons of technical feasibility of the device. A second
generation POCT will test anti-MCV and RF-IgM, the
only laboratory classification criterion for RA to date. A
clinical sensitivity of 54.6% for the detection of anti-MCV
may be due to the fact that almost all patients have been
under treatment which might act on the detectability of
the antibodies. ELISA's analyses showed 75% sensitivity;
this gap is most likely explained by reason of slightly dif-
ferent epitopes. In 2008, Snijders et al. reported on a
POCT testing for anti-CCP2 antibodies from capillary
blood of 109 RA patients showing 95% sensitivity and
95% specificity regarding ELISA's results [15].
Conclusions
Recent developments reflect the need for simple and
quick tools in helping to spot patients at high risk for an
aggressive course of disease in order to optimize manage-
ment of RA.
In summary, this novel rapid test system for the detec-
tion of disease specific autoantibodies can significantly
improve a timely management of RA and may help in
screening patients with suspected RA, prompting early
referrals even in non-specialized settings.
Additional material
Additional file 1 Supplementary table. Diagnoses of the control groups.
Table 3: Results of POCT for different patients' groups and controls
Results RA (n) Control 
group (n)
Blood 
donors (n)
Total (n)
MCV+ RF IgG+ 46 0 3 49
MCV+ RF IgG- 13 0 0 13
MCV- RF IgG+ 15 10 13 38
MCV- RF IgG- 34 112 184 330
total 108 122 200 430Renger et al. Arthritis Research & Therapy 2010, 12:R120
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